Furthermore, randomized controlled trials (RCTs) also show a significantly reduced incidence of CSCC in patients receiving mTOR inhibitors compared to cyclosporine [51], as well as in patients who were prescribed sirolimus after three months of treatment with cyclosporine (1.2% vs. 4.3%, p < 0.001) [43,52]. The gene discussed is MTOR; the disease is skin squamous cell carcinoma.